|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Genmark Diagnostics, Inc. (GNMK) |
|
|
$24.04 0.00 (0.00%) as of 4:30 Tue 4/20
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
71,720,000 |
| Market
Cap: |
1.72(B) |
| Last
Volume: |
8,115 |
Avg
Vol: |
8,092 |
| 52
Week Range: |
$24.04 - $24.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shaw Christine |
VP, Assay Development |
• – – |
2021-03-05 |
4 |
S |
$18.56 |
$5,085 |
D/D |
(274) |
102,196 |
|
-24% |
|
| Jensen Tyler |
SVP, Engineering and Tech Dev |
• – – |
2021-03-04 |
4 |
AS |
$18.86 |
$9,430 |
D/D |
(500) |
212,388 |
|
29% |
|
| Obrien Scott Alexander |
SVP, Global Mktg & Intl Sales |
• – – |
2021-03-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(735) |
170,879 |
|
- |
|
| Maderazo Alan Baer |
VP, Qual, Reg, & Clin Affairs |
• – – |
2021-03-01 |
4 |
AS |
$19.19 |
$40,817 |
D/D |
(2,127) |
262,180 |
|
26% |
|
| Shaw Christine |
VP, Assay Development |
• – – |
2021-02-26 |
4 |
S |
$17.03 |
$53,662 |
D/D |
(3,151) |
102,470 |
|
-23% |
|
| Gleeson Michael |
SVP, Corp. Accounts |
• – – |
2021-02-26 |
4 |
S |
$17.01 |
$301,928 |
D/D |
(17,750) |
392,743 |
|
-23% |
|
| Harkins Michael John |
SVP, Sales |
• – – |
2021-02-26 |
4 |
S |
$17.03 |
$210,848 |
D/D |
(12,381) |
143,611 |
|
-23% |
|
| Winkler Sarah Hollis |
VP, Human Resources |
• – – |
2021-02-26 |
4 |
S |
$17.01 |
$190,189 |
D/D |
(11,181) |
147,502 |
|
-23% |
|
| Mendel Scott |
President & CEO |
• • – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(41,834) |
507,198 |
|
- |
|
| Obrien Scott Alexander |
SVP, Global Mktg & Intl Sales |
• – – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,726) |
171,614 |
|
- |
|
| Jensen Tyler |
SVP, Engineering and Tech Dev |
• – – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,734) |
212,888 |
|
- |
|
| Ek John Frederick |
Chief Financial Officer |
• – – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(19,248) |
232,993 |
|
- |
|
| Stier Eric |
SVP & General Counsel |
• – – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,642) |
275,974 |
|
- |
|
| Maderazo Alan Baer |
VP, Qual, Reg, & Clin Affairs |
• – – |
2021-02-25 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,946) |
264,307 |
|
- |
|
| Maderazo Alan Baer |
VP, Qual, Reg, & Clin Affairs |
• – – |
2021-02-25 |
4 |
AS |
$19.16 |
$5,097 |
D/D |
(266) |
278,253 |
|
28% |
|
| Shaw Christine |
VP, Assay Development |
• – – |
2021-02-24 |
4 |
S |
$19.12 |
$4,952 |
D/D |
(259) |
105,621 |
|
-25% |
|
| Gleeson Michael |
SVP, Corp. Accounts |
• – – |
2021-02-24 |
4 |
S |
$19.12 |
$47,093 |
D/D |
(2,463) |
410,493 |
|
-25% |
|
| Maderazo Alan Baer |
VP, Qual, Reg, & Clin Affairs |
• – – |
2021-02-24 |
4 |
AS |
$19.12 |
$3,117 |
D/D |
(163) |
280,263 |
|
25% |
|
| Jensen Tyler |
SVP, Engineering and Tech Dev |
• – – |
2021-02-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,163) |
229,622 |
|
- |
|
| Mendel Scott |
President & CEO |
• • – |
2021-02-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,254) |
549,032 |
|
- |
|
| Shaw Christine |
VP, Assay Development |
• – – |
2021-02-23 |
4 |
S |
$19.35 |
$3,212 |
D/D |
(166) |
105,880 |
|
-25% |
|
| Gleeson Michael |
SVP, Corp. Accounts |
• – – |
2021-02-23 |
4 |
S |
$19.35 |
$27,709 |
D/D |
(1,432) |
412,956 |
|
-25% |
|
| Obrien Scott Alexander |
SVP, Global Mktg & Intl Sales |
• – – |
2021-02-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(735) |
181,340 |
|
- |
|
| Ek John Frederick |
Chief Financial Officer |
• – – |
2021-02-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(908) |
252,241 |
|
- |
|
| Maderazo Alan Baer |
VP, Qual, Reg, & Clin Affairs |
• – – |
2021-02-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,744) |
278,519 |
|
- |
|
854 Records found
|
|
Page 2 of 35 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
